Answers are grounded in this paper and cite their sources.
BACKGROUND: Dental, oral, and craniofacial regenerative medicine has benefitted from fundamental scientific discoveries, yet the resulting technologies and therapies do not always generate the anticipated clinical impact. Despite robust progress and substantial investment in biomaterials and tissue engineering, few breakthroughs have achieved widespread adoption in the clinical arena. TYPES OF STUDIES REVIEWED: The authors analyzed the translational bottlenecks, such as regulatory complexity, gaps in meaningful clinical evidence, and economic and cultural barriers, that have limited the impact of even US Food and Drug Administration-approved technologies. RESULTS: The authors highlight successful strategies from the Translational Resource Center, emphasize the importance of milestone-driven development and early clinical and stakeholder input, and propose a right-to-left translational paradigm that frames clinical adoption as the ultimate goal from project inception. CONCLUSIONS AND PRACTICAL IMPLICATIONS: By means of advocating for clinical evidence and outcomes that resonate with both patients and providers, the authors outlined a new road map for bridging the gap between emerging technologies and clinical impact.
No takes yet. Share an insight, caveat, or question.
Swanson et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: